Glaxosmithkline Share News (GSK)

TOP NEWS: UK Trade Gap Unexpectedly Widens In June

M&A boost on euro bond market horizon

* Euro corporate bond market gears up for bumper H2 * More hybrid deals expected * M&A borrowers face leverage risks By Laura Benitez August 8 (IFR) - The European corporate bond market is expected to reload early after the summer break and is gearing up for a bumper secon

UK MORNING BRIEFING: Catlin Leads FTSE 350 Amid Nervous Market

Friday newspaper round-up: Iraq, Tesco, RBS...

Barack Obama has authorised targeted air strikes against Islamic militants in Iraq, as the US military began an airborne operation to bring relief to thousands of minority Iraqis driven to a grim, mountain-top refuge. Describing the threats against stranded Yezidi refugees as holding the potential f

PRESS: Glaxo China Investigator Trial Starts; Hampton Lined Up As Chairman - FT

GSK-linked investigators stand trial in China in closely watched case

By Brenda Goh SHANGHAI, Aug 8 (Reuters) - A British investigator and his American wife will stand trial in Shanghai on Friday in a case that is seen as key to a bribery investigation against GlaxoSmithKline Plc and has unnerved the growing community of corporate sleuths in China. Pete

Scientists retract narcolepsy study linked to GSK vaccine

LONDON, Aug 7 (Reuters) - Scientists who believed they had started to decipher links between a GlaxoSmithKline H1N1 pandemic flu vaccine and the sleep disorder narcolepsy have retracted a study after saying they cannot replicate their findings. The paper, originally published in the journal

GSK close to picking RBS's Hampton as next chairman -Sky

LONDON, Aug 7 (Reuters) - GlaxoSmithKline, Britain's biggest drugs company, is close to appointing Philip Hampton as its next chairman, in a move that will coincide with his departure from Royal Bank of Scotland, Sky News said on Thursday. Sky said GSK could announce Hampton's appointment n

FTSE 100 movers: Pharma stocks drop as regulation looks to derail M&A

Shire, the pharmaceutical group which has agreed to a £32bn takeover by Abbvie, saw its shares decline sharply on Wednesday on concerns that stricter rules on so-called 'tax inversion' in the States could scupper the deal. Sector peer Astrazeneca, which had recently been the target of a failed £69b

Sector movers: Shire and AZN lead pharma stocks lower on M&A risk

The pharmaceutical sector dropped on Wednesday on the back of fears about risks to mergers and acquisitions (M&A) activity, with Shire sinking sharply. Concerns that stricter rules on so-called 'tax inversion' in the US could scupper Abbvie's £32bn takeover of London-listed Shire dented the latter'

London midday: FTSE 100 near 6,600 as Ukraine crisis sinks stocks

- Russian troops amass along Ukraine border - UK, Italian and German data disappoints - Ex-dividend stocks fall - StanChart falls after results, Shire drops FTSE 100 6,604.48 -1.17% FTSE 250 15,162.03 -1.24% techMARK 2,708.06 -1.23% Fears about a possible Russian invasion of Ukraine sparked a sell

UK WINNERS & LOSERS: Pharmaceuticals Hit By Scrutiny Of Tax Inversion

London open: UK stocks drop as Ukraine crisis intensifies

- Russia builds up troop numbers along border - German factory orders slump 3.2% - Ex-div stocks fall, Sage rises after appointing new CEO techMARK 2,728.84 -0.47% FTSE 100 6,646.91 -0.53% FTSE 250 15,263.85 -0.57% UK stocks dropped on Wednesday morning as heightened geopolitical tensions hit risk

UK Dividends Calendar - Week Ahead

UPDATE 1-Drug company won't appeal gay rights ruling to top U.S. court

(Adds details about case) By Dan Levine SAN FRANCISCO, Aug 5 (Reuters) - An appeals court ruling that extended landmark constitutional protections for gays and lesbians will not be appealed to the U.S. Supreme Court, a spokesman for one of the drug companies in the case said on Tuesda